1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Rat |
Cat.No | ABC-TC4069 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Endothelial |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Aortic |
Disease | Normal |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Rat Primary Cells |
Rat Aortic Endothelial Cells (RAECs) are primary cells isolated from the aortic tissue of rats. These cells exhibit adherent growth and display typical endothelial cells morphology. Functionally, RAECs regulate vascular tone by secreting vasoactive factors such as nitric oxide (NO), and they actively modulate inflammatory responses. RAECs are implicated in atherosclerosis, diabetic vascular complications, and hypertension-related endothelial dysfunction, particularly under conditions of oxidative stress or chronic inflammation. These cells demonstrate high expression of endothelial-specific markers, including CD31 (PECAM-1) and von Willebrand factor (vWF). RAECs maintain functional characteristics in early passages. Their sensitivity to shear stress and cytokine-mediated activation makes them particularly suitable for modeling vascular pathophysiology in vitro.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Rat Aortic Endothelial Cells (RAEC) offer a robust in vitro model for investigating cardiovascular function and disease mechanisms, including vascular inflammation, immune-mediated damage, and endothelial dysfunction. They play an important role in research related to the immune system, graft rejection, and the development of 3D endothelialized tissues construct. Moreover, RAEC support research in vascular regeneration, drug screening, and the evaluation of novel therapeutic agents targeting endothelial health.